PARASAL
Pre-Launchaminosalicylic acid
NDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
2
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PARASAL (aminosalicylic acid) is an oral tablet small molecule indicated for treatment of tuberculosis, particularly drug-resistant forms. The drug works as a bacteriostatic agent that inhibits mycobacterial growth by interfering with folate synthesis and nucleic acid metabolism. It is typically used as part of multi-drug regimens in combination with other anti-tuberculous agents.
Pre-Launch
Pre-launch stage indicates early-stage commercial planning; team building and go-to-market strategy development are underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea
Started Oct 2021
11,385 enrolled
Ulcerative Colitis
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
Started Jan 2012
510 enrolled
Ulcerative Colitis
Career Relevance
Working on PARASAL offers exposure to rare disease commercialization, global health impact, and complex multi-stakeholder engagement across WHO, NGOs, and regional health authorities. Pre-launch phase provides career leverage in establishing brand positioning, medical evidence strategies, and access programs in underserved markets.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.